Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_assertion type Assertion NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_head.
- NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_assertion description "[These results indicate that HNSCC cells expressing high-risk p53 mutations are significantly sensitized to cisplatin therapy by the selective wee-1 kinase inhibitor, supporting the clinical evaluation of MK-1775 in combination with cisplatin for the treatment of patients with TP53 mutant HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_provenance.
- NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_assertion evidence source_evidence_literature NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_provenance.
- NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_assertion SIO_000772 25504633 NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_provenance.
- NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_assertion wasDerivedFrom befree-2016 NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_provenance.
- NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_assertion wasGeneratedBy ECO_0000203 NP1248057.RAQBWKp9_jhWIdBIzHKEKmny1UFoEb-ZrSX-7DD5J17W4130_provenance.